v3 Template
K

Khondrion

Biopharmaceutical ~220 employees
Founded
--
Employees (Est.)
~220
11 leaders known
Total Funding
$5.4M
Funding Rounds
1
Last Funding
2025-05-06

About Khondrion

Khondrion is a clinical-stage biopharmaceutical company focused on discovering and developing therapies targeting mitochondrial disease. The company is based on proprietary science and a deep understanding of mitochondrial dysfunction, with a mission to bring energy to life through innovative treatments.

Products & Services

Sonlicromanol:A wholly owned lead drug candidate for the treatment of mitochondrial diseases in both children and adults.

Specialties

Mitochondrial disease therapies Drug development for oxidative phosphorylation defects Proprietary science in mitochondrial dysfunction

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Government Grant and Private Investment
T: -
FT: Government Grant and Private Investment
A: 5400000
MR: -
FA: up to €5 Million
FAN: 5400000
D: 2025-05-06
FD: 2025-05-06
2 investors
Government Grant and Private Investment Latest
2025-05-06
$5.4M
2 investors (Pro only)

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

J

Jan Smeitink

Chief Executive Officer

LinkedIn (Pro only)
H

Herma Renkema

Chief Scientific Officer

LinkedIn (Pro only)
J

Jasper Levink

Chief Financial Business Officer

LinkedIn (Pro only)
D

Doug Turnbull

Professor of Neurology, Newcastle University

M

Marni Falk

Executive Director, CHOP Mitochondrial Medicine Frontier Program and Professor, Division of Human Genetics, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, USA

M

Michelangelo Mancuso

Professor of Neurology, Department of Clinical and Experimental Medicine, Neurological Institute, University of Pisa, Italy; Chair, Neurogenetics and Rare Diseases Panel - Italian Society of Neurology; Chair, Neurogenetics Panel of the European Academy of Neurology

View 8 more team members with Pro

Unlock Full Team Directory

Recent News

Khondrion Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biopharmaceutical
Company Size
~220 employees (est.)

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro